SIGLEC5

Summary

SIGLEC5 (sialic acid binding Ig like lectin 5, HGNC:10874) is a long non-coding RNA gene on chromosome 19q13.41. Putative adhesion molecule that mediates sialic-acid dependent binding to cells.

This gene encodes a member of the sialic acid-binding immunoglobulin-like lectin (Siglec) family. These cell surface lectins are characterized by structural motifs in the immunoglobulin (Ig)-like domains and sialic acid recognition sites in the first Ig V set domain. The encoded protein is a member of the CD33-related subset of Siglecs and inhibits the activation of several cell types including monocytes, macrophages and neutrophils. Binding of group B Streptococcus (GBS) to the encoded protein plays a role in GBS immune evasion.

Source: NCBI Gene 8778 — RefSeq curated summary.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).
• Dosage sensitivity (ClinGen): haploinsufficiency dosage sensitivity unlikely, triplosensitivity no evidence

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10874
Approved symbol	SIGLEC5
Name	sialic acid binding Ig like lectin 5
Location	19q13.41
Locus type	gene with protein product
Status	Approved
Aliases	OB-BP2, SIGLEC-5, CD170
Ensembl gene	ENSG00000105501
Ensembl biotype	lncRNA
OMIM	604200
Entrez	8778

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 lncRNA

ENST00000534261

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000534261 — 3 exons

Exon	Start	End
ENSE00002156182	51630299	51630666
ENSE00002188877	51645477	51645545
ENSE00003475926	51630101	51630216

Expression profiles

Bgee: expression breadth ubiquitous, 120 present calls, max score 93.38.

Top tissues by expression

130 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	93.38	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.10	gold quality
leukocyte	CL:0000738	85.42	gold quality
monocyte	CL:0000576	85.41	gold quality
granulocyte	CL:0000094	83.10	gold quality
spleen	UBERON:0002106	79.85	gold quality
bone marrow	UBERON:0002371	77.98	gold quality
bone marrow cell	CL:0002092	74.15	gold quality
vermiform appendix	UBERON:0001154	74.15	gold quality
lymph node	UBERON:0000029	70.53	gold quality
right lung	UBERON:0002167	67.66	gold quality
upper lobe of left lung	UBERON:0008952	64.12	gold quality
placenta	UBERON:0001987	63.58	gold quality
smooth muscle tissue	UBERON:0001135	62.76	gold quality
apex of heart	UBERON:0002098	59.42	gold quality
small intestine Peyer’s patch	UBERON:0003454	59.26	gold quality
lung	UBERON:0002048	59.19	gold quality
rectum	UBERON:0001052	57.78	gold quality
gall bladder	UBERON:0002110	57.13	gold quality
small intestine	UBERON:0002108	56.56	gold quality
omental fat pad	UBERON:0010414	55.19	gold quality
descending thoracic aorta	UBERON:0002345	54.23	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	52.67	gold quality
mucosa of transverse colon	UBERON:0004991	51.54	gold quality
left uterine tube	UBERON:0001303	51.30	gold quality
adipose tissue	UBERON:0001013	50.91	gold quality
right lobe of liver	UBERON:0001114	50.49	gold quality
right coronary artery	UBERON:0001625	50.47	gold quality
hindlimb stylopod muscle	UBERON:0004252	50.43	gold quality
putamen	UBERON:0001874	50.12	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

43 targeting SIGLEC5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4500	99.99	72.72	2367
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-LET-7D-5P	99.96	71.76	1632
HSA-MIR-4458	99.96	71.64	1650
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-202-3P	99.84	71.41	1290
HSA-MIR-3679-3P	99.64	69.88	1599
HSA-MIR-5003-5P	99.61	69.13	1624
HSA-MIR-3128	99.50	67.85	1258
HSA-MIR-302A-5P	99.39	68.21	1913
HSA-MIR-361-3P	99.19	66.45	1381
HSA-MIR-6809-5P	99.13	68.45	1223
HSA-MIR-29A-5P	99.08	68.59	1813
HSA-MIR-3124-3P	98.87	68.95	2123
HSA-MIR-5006-5P	98.79	66.92	1246
HSA-MIR-4755-3P	98.77	65.59	1915
HSA-MIR-4317	98.49	67.09	987

Functional genomics

ClinGen dosage: haploinsufficiency 40 (dosage sensitivity unlikely), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 25)

• expression of Siglec-5 on cells of the myelomonocytic lineage and alteration of its expression by inflammatory stimuli suggest a role for this protein in cell/cell interactions following microbial exposure. (PMID:12763136)
• Siglec-5 can be classified as an inhibitory receptor with the potential to mediate SHP-1 and/or SHP-2-dependent signaling in the absence of tyrosine phosphorylation. (PMID:15769739)
• Siglecs-5 did not interact with sulfate derivatives of LacNAc and sulfated oligosaccharides containing sialic acid. (PMID:16732727)
• The expression levels of Siglec-5 were high or detectable in bone marrow plasma from AML patients and serum from normal donors. (PMID:16828866)
• Siglec-14 and Siglec-5 appear to be the first glycan binding paired receptors. Near-complete sequence identity of the amino-terminal part of human Siglec-14 and Siglec-5 indicates partial gene conversion between SIGLEC14 and SIGLEC5. (PMID:17012248)
• Siglec-5 is identified as a receptor for alpha-1-acid glycoprotein (AGP) 1 in human neutrophils. (PMID:17675532)
• Structural implications of SIGLEC5-mediated sialoglycan recognition are reported. (PMID:18022638)
• Group B Streptococcus beta protein binding to Siglec-5 functions to impair leukocyte phagocytosis, oxidative burst, and extracellular trap production, promoting bacterial survival. (PMID:19596804)
• Siglec-5 expression correlates with lack of proliferation in a subset of human cells, and is upregulated by activation of chimpanzee but not human lymphocytes. (PMID:20231688)
• Human Siglec-5 inhibitory receptor and immunoglobulin A (IgA) have separate binding sites in streptococcal beta protein. (PMID:21795693)
• Siglec-5 expression protects T cells from HIV-1- and apoptosis-induced cell death and contributes to the different outcomes of HIV-1 infection in humans and chimpanzees. (PMID:22945238)
• These studies demonstrate the Siglec5 carbohydrate recognition domain alone is sufficient for binding sialylated carbohydrates and provide a foundation for further investigation of Siglec5 structure and function. (PMID:23321067)
• we found that secretory IgA is taken up by M cells via the Dectin-1 receptor, with the possible involvement of Siglec-5 acting as a co-receptor. (PMID:24068891)
• Data indicate that the Siglec-5/14 genotype influences neutrophil responses to group B Streptococcus. (PMID:24799499)
• An unbiased screen revealed Hsp70 as a ligand for Siglec-5 and Siglec-14. Hsp70 stimulation through Siglec-5 delivers an anti-inflammatory signal, while stimulation through Siglec-14 is pro-inflammatory. (PMID:26459514)
• PSGL1 and Siglec-5 are in close proximity at the leukocyte surface.SPSGL1 is a ligand for Siglec-5 and interacts with Siglec-5 ectodomain.Siglec-5 plays a role in PSGL1-mediated leukocyte rolling and the inflammatory response in general. (PMID:27892504)
• Plasma Siglec-5 levels are implicated as an early diagnostic marker of CLI in T2DM patients and it may become a target for the prevention or treatment of CLI in diabetes. (PMID:28900239)
• Genetic susceptibility of common polymorphisms in NIN and SIGLEC5 to chronic periodontitis. (PMID:30765789)
• Soluble siglec-5 is a novel salivary biomarker for primary Sjogren’s syndrome. (PMID:30922727)
• Periodontitis Risk Variants at SIGLEC5 Impair ERG and MAFB Binding. (PMID:34852650)
• Siglec-5 is an inhibitory immune checkpoint molecule for human T cells. (PMID:35290663)
• Siglec-5 and Siglec-14 mediate the endocytosis of ADAMTS13. (PMID:36116391)
• Case-only design identifies interactions of genetic risk variants at SIGLEC5 and PLG with the lncRNA CTD-2353F22.1 implying the importance of periodontal wound healing for disease aetiology. (PMID:36129033)
• PSGL-1: a novel immune checkpoint driving T-cell dysfunction in obstructive sleep apnea. (PMID:37854605)
• The prognostic impact of SIGLEC5-induced impairment of CD8[+] T cell activation in sepsis. (PMID:37890368)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.